NEWSROOM
News Releases
The latest news about Samsung Bioepis
Samsung Bioepis Earns ISO Certification for Compliance Management Systems
• Obtains ISO 37301 (Compliance Management Systems), underscoring the company’s commitment to ensuring adherence to laws, regulations and ethical standards
INCHEON, Korea – July 18, 2025 – Samsung Bioepis Co., Ltd. today announced that it has received a certification on ISO 37301 (Compliance Management Systems) from the British Standards Institution (BSI), underscoring the company’s commitment to ensuring adherence to laws, regulations and ethical standards and fostering a culture of integrity.
“This ISO certification is a testament that Samsung Bioepis upholds highest standards for compliance to regulations and organizational governance,” said Kyung-Ah Kim, President and Chief Executive Officer at Samsung Bioepis. “We will keep implementing rigorous standards and practices in our compliance management system to continue to build trust and enhance our reputation among our stakeholders.”
ISO 37301 is an international standard for compliance management systems (CMS). It provides guidelines for establishing, developing, implementing, evaluating, maintaining, and improving an effective and responsive compliance management system within organizations.1
The latest ISO certification follows the company’s four ISO certifications, ISO 27001 (Information Security Management System) and ISO 45001 (Occupational Health & Safety Management System) received in August 2023 and ISO 14001 (Environmental Management System) and ISO 50001 (Energy Management System) received in September 2022.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – LinkedIn, X.
MEDIA CONTACT
Anna Nayun Kim, nayun86.kim@samsung.com
Yoon Kim, yoon1.kim@samsung.com
1 International Organization for Standardization. ISO 37301:2021 - Compliance management systems. Available at: https://www.iso.org/standard/75080.html
